ENGN insider trading — enGene Therapeutics Inc.
Over the last 90 days, insiders at enGene Therapeutics Inc. (ENGN) made 1 open-market purchase worth $10K and 0 open-market sales worth $0, making them net buyers by $10K. The largest purchase was by Grossman William (Interim Chief Medical Officer), who bought 5,102 shares for $10K on Sep 22, 2026.
Updated Oct 16, 2026.
Recent ENGN insider transactions
Every Form 4 filed by enGene Therapeutics Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Grossman William | Interim Chief Medical Officer | P · Purchase | Direct | 5,102 | $1.97 | $10K | Form 4 |
ENGN insider trading FAQ
Are insiders buying ENGN stock?
Yes. In the last 90 days, enGene Therapeutics Inc. insiders made 1 open-market purchase totaling $10K, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading ENGN?
Recent buyers: Grossman William.
Where does ENGN insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.